Brazil mpox cases pass 1,000 as clade Ib spreads

Brazil has passed 1,000 confirmed mpox cases in 2026, after a sharp acceleration in infections over the past two months driven by a newer lineage of the virus, according to the country’s Ministry of Health.
The ministry’s epidemiological panel counted 1,023 confirmed cases as of Thursday, 12 November, alongside 46 probable cases still being classified and 581 under investigation. One death has been recorded this year. Just six days earlier, the same panel stood at 832 cases, a rise of 191 confirmations, or roughly 23 per cent.
By Friday the panel had moved again, to 1,055 cases, according to Folha de S.Paulo. The ministry’s figures show 293 confirmations in October and 227 already in November, meaning more than half of everything Brazil has recorded in 2026 has come in those two months.
Cases concentrated in Rio and São Paulo
The outbreak is heavily concentrated in two states. Rio de Janeiro has recorded 390 confirmed cases and São Paulo 388, together accounting for about three-quarters of the national total. They are followed by Ceará with 61, Minas Gerais with 45, the Federal District with 41 and Santa Catarina with 24.
Rio’s state total is already more than triple the 123 cases it recorded in all of 2025. In the city of Rio alone, 74 cases were logged over the past two months, seven times the figure for the same period last year.
Clade Ib now dominant in Rio
What most concerns health officials is the lineage behind the rise. The 2022 global outbreak, which produced about 10,500 cases in Brazil, was driven by clade IIb. The strain gaining ground now is clade Ib, first identified in eastern Democratic Republic of Congo in 2023 and the reason the World Health Organization declared a public health emergency of international concern in August 2024, a declaration it later ended.
The first clade Ib infection in Rio was detected in March 2026, in a patient seen at the Fiocruz national institute of infectology. Since September, 73 per cent of Rio cases with a clade result available have been clade Ib, according to the state health secretariat. Researchers at the Federal University of Rio de Janeiro found the subclade in 20 of 35 samples taken in November.
São Paulo’s picture is similar, though less advanced. The state’s Adolfo Lutz Institute has identified clade Ib in 103 cases this year, concentrated in the São Paulo metropolitan region. In 2025 the state recorded 423 cases, and exactly one of them was clade Ib.
One death and the vaccine response
Brazil has recorded one mpox death in 2026, in Rio de Janeiro. State health authorities said the patient was aged between 40 and 49 and had a pre-existing immunosuppressive condition. The ministry’s own comparison shows 54 hospital admissions for mpox this year, against 254 in 2022.
On 8 November the Ministry of Health announced it had secured 25,000 doses of mpox vaccine after negotiating with the Danish manufacturer, Bavarian Nordic, through the Pan American Health Organization’s revolving fund. Delivery is expected within three weeks. Rio has received about 2,000 doses so far and is vaccinating immunosuppressed people first.
There is no mass vaccination programme, in line with World Health Organization advice. The vaccine is offered to people living with HIV within specified CD4 thresholds, to users of HIV pre-exposure prophylaxis, to laboratory staff who handle mpox samples and to people who have had medium- or high-risk contact, in two doses 28 days apart. To stretch scarce supplies, the ministry has directed states to switch to intradermal application, delivering a fifth of the dose into the skin, which can cover up to five times as many people in the specified groups.
Mpox still has no proven specific treatment. Its symptoms include skin lesions, which can also appear in the mouth, on the genitals or around the anus, together with fever, swollen lymph nodes or rectal pain. Anyone with new lesions should seek assessment and avoid close contact until seen.
Sources: Global 1 News and Particle News.